Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 May;40(3):165–172. doi: 10.1007/BF01517348

CD8+T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (GLY13→ASP), are cytotoxic towards a carcinoma cell line harbouring the same mutation

Beate Fossum 1, Anna Catharina Olsen 2, Erik Thorsby 1, Gustav Gaudernack 1,✉
PMCID: PMC11037639  PMID: 7728775

Abstract

Several T lymphocyte clones (TLC), specific for a p21-Ras-derived peptide expressing a Gly13→Asp mutation and of the CD8+ subtype, were generated from peripheral blood of a colon carcinoma patient. The TLC exerted cytotoxicity against an interferon-γ (IFNγ)-pretreated colon carcinoma cell line, HCT116, which harbours the Gly13→Asp mutation and shares both HLA-A2 and HLA-B12(44) with the patient. This cytotoxic effect could be blocked by a monoclonal antibody (mAb) against CD8 molecules, as well as with a mAb against HLA class I molecules and a polyclonal antiserum against HLA-B12, identifying B12(44) as the antigen-presenting molecule. In growth-inhibition experiments, the growth of both IFNγ-pretreated and untreated target cells were strongly inhibited by the presence of the CD8+TLC. Together these data indicate that human cancer cells harbouring a spontaneousras mutation can process aberrant p21 Ras and express peptide/HLA-class-I complexes on their surface in sufficient density to be recognized by Ras-specific cytotoxic T lymphocytes.

Key words: Mutant p21 Ras, Colon carcinoma, Cytotoxic T cells, HLA-B12(44)

References

  • 1.Bodmer JG, Moses JH, Marsh SGE. In: Proceedings of the 11th International Histocompatibity Workshop and Conference, vol. 1. Tsuji K, Aisawa M, Sasazuki T, editors. Oxford: Oxford Science Publications; 1992. p. 264. [Google Scholar]
  • 2.Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682. [PubMed] [Google Scholar]
  • 3.Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer. 1994;69:367. doi: 10.1038/bjc.1994.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Falo LD, Colarusso LJ, Benacerraf B, Rock KL. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc Natl Acad Sci USA. 1992;89:8347. doi: 10.1073/pnas.89.17.8347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL. Cytotoxic T cell response and in vivo protection against tumor cells harboring activatedras protooncogenes. J Natl Cancer Inst. 1993;85:1294. doi: 10.1093/jnci/85.16.1294. [DOI] [PubMed] [Google Scholar]
  • 6.Fossum B, Gedde-Dahl T, III, Hansen T, Eriksen JA, Thorsby E, Gaudernack G. Overlapping epitopes encompassing a point mutation (12Gly→Arg) in p21 ras can be recognized by HLA-DR,-DP and-DQ restricted T cells. Eur J Immunol. 1993;23:2687. doi: 10.1002/eji.1830231045. [DOI] [PubMed] [Google Scholar]
  • 7.Fossum B, Gedde-Dahl T, III, Brevik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly→Asp) Int J Cancer. 1994;56:40. doi: 10.1002/ijc.2910560108. [DOI] [PubMed] [Google Scholar]
  • 8.Fossum B, Breivik J, Meling GI, Gedde-Dahl T, III, Hansen T, Knutsen I, Rognum TO, Thorsby E, Gaudernack G. A K-ras 13Gly→Asp mutation is recognized by HLA-DQ7 restricted T cell in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation. Int J Cancer. 1994;58:506. doi: 10.1002/ijc.2910580409. [DOI] [PubMed] [Google Scholar]
  • 9.Gaudernack G, Leivestad T, Ugelstad J, Thorsby E. Isolation of pure functionally active CD8+ T cells. Positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres. J Immunol Methods. 1986;90:179. doi: 10.1016/0022-1759(86)90074-8. [DOI] [PubMed] [Google Scholar]
  • 10.Gedde-Dahl T, III, Spukland A, Eriksen JA, Thorsby E, Gaudernack G. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 res (Gln→Leu61) Int Immunol. 1992;4:1331. doi: 10.1093/intimm/4.11.1331. [DOI] [PubMed] [Google Scholar]
  • 11.Gedde-Dahl T, III, Eriksen JA, Thorsby E, Guudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 rasderived synthetic peptides. Human Immunol. 1992;33:266. doi: 10.1016/0198-8859(92)90334-j. [DOI] [PubMed] [Google Scholar]
  • 12.Gedde-Dahl T, III, Fossum B, Eriksen JA, Thorsby E, Gaudernack G. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction. Eur J Immunol. 1993;23:754. doi: 10.1002/eji.1830230328. [DOI] [PubMed] [Google Scholar]
  • 13.Jiang W, Kahn SM, Guillen JG, Lu SH, Weinstein IB. Rapid detection ofras oncogenes in human tumors: applications to colon, esophageal, and gastric cancer. Oncogene. 1989;4:923. [PubMed] [Google Scholar]
  • 14.Jung S, Scluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med. 1991;173:273. doi: 10.1084/jem.173.1.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rønningen KS, Spurkland A, Markussen G, Iwe T, Vartdal F, Thorsby E. Distribution of HLA class II alleles among Norwegian caucasians. Hum Immunol. 1990;29:275. doi: 10.1016/0198-8859(90)90041-m. [DOI] [PubMed] [Google Scholar]
  • 16.Skipper J, Stauss HJ. Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J Exp Med. 1993;177:1493. doi: 10.1084/jem.177.5.1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vanky F, Wang P, Patarroyo M, Klein E. Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother. 1990;31:19. doi: 10.1007/BF01742491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Vartdal F, Gaudernack G, Funderud S, Bratlie A, Lea T, Ugelstad J, Thorsby E. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation —a fast and reliable technique. Tissue Antigens. 1986;28:301. doi: 10.1111/j.1399-0039.1986.tb00500.x. [DOI] [PubMed] [Google Scholar]
  • 19.Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525. doi: 10.1056/NEJM198809013190901. [DOI] [PubMed] [Google Scholar]
  • 20.Wölfel T, Klehmann E, Müller C, Schütt K-H, Meyerzum Büschenfelde K-H, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leucocyte antigen A2 as a restriction element for three different antigens. J Exp Med. 1989;170:797. doi: 10.1084/jem.170.3.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wölfel T, Herr W, Coulie P, Schmitt U, Meyer zum Büschenfelde K-H, Knuth A. Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer. 1993;54:636. doi: 10.1002/ijc.2910540419. [DOI] [PubMed] [Google Scholar]
  • 22.Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Büschenfelde K-H, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994;24:759. doi: 10.1002/eji.1830240340. [DOI] [PubMed] [Google Scholar]
  • 23.Yang Y, Waters JB, Früh K, Peterson PA. Proteasomes are regulated by interferon gamma: implications for antigen processing. Proc Natl Acad Sci USA. 1992;89:4928. doi: 10.1073/pnas.89.11.4928. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES